An IL-2 Receptor Targeted Toxin with Reduced VLS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI063910-01
Agency Tracking Number: AI063910
Amount: $144,786.00
Phase: Phase I
Program: SBIR
Awards Year: 2005
Solicitation Year: 2005
Solicitation Topic Code: N/A
Solicitation Number: PHS2005-2
Small Business Information
10 Chilhowie Ct., Cockeysville, MD, 21030
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JOHANNA VANDERSPEK
 (410) 561-1434
 ANJIN_GROUP@EARTHLINK.NET
Business Contact
Phone: (508) 831-6383
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Well over a decade ago the first diphtheria toxin-based fusion protein toxin, DAB389IL-2 (Ontak(R)) was in development as the first of a new class of receptor specific therapeutic agent. This fusion protein gained FDA approval five years ago for the treatment of refractory cutaneous T cell lymphoma. The fusion protein toxin technology has not been widely developed due adverse events, especially vascular leak syndrome (VLS), associated with administration of these agents. The Anjin Group Inc [AGI] proposes to develop a third generation diphtheria toxin-based platform, modified to reduce VLS. Fusion protein toxins developed from such a toxophore may have broader clinical application due to an altered risk benefit profile for patients including those with non-life threatening disease.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government